RecruitingPHASE1, PHASE2NCT00967785

A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

Studying Acquired neutropenia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator: David H McDermott, M.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Intervention: Mozobil (TM)(drug)
Enrollment: 20 enrolled
Eligibility: 18-75 years · All sexes
Timeline: 2010 – 2026

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00967785 on ClinicalTrials.gov

Other trials for Acquired neutropenia

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE3NCT06056297
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
X4 Pharmaceuticals

See all trials for Acquired neutropenia →

← Back to all trials